- Home
- ACAD vs LEU Comparison
ACAD vs LEU Comparison
Compare ACAD & LEU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACAD
- LEU
- Stock Information
- Founded
- ACAD 1993
- LEU 1998
- Country
- ACAD United States
- LEU United States
- Employees
- ACAD N/A
- LEU N/A
- Industry
- ACAD Biotechnology: Pharmaceutical Preparations
- LEU Mining & Quarrying of Nonmetallic Minerals (No Fuels)
- Sector
- ACAD Health Care
- LEU Industrials
- Exchange
- ACAD Nasdaq
- LEU Nasdaq
- Market Cap
- ACAD 4.0B
- LEU 4.2B
- IPO Year
- ACAD 2004
- LEU 1998
- Fundamental
- Price
- ACAD $25.99
- LEU $201.55
- Analyst Decision
- ACAD Buy
- LEU Buy
- Analyst Count
- ACAD 20
- LEU 11
- Target Price
- ACAD $28.63
- LEU $194.80
- AVG Volume (30 Days)
- ACAD 2.0M
- LEU 1.7M
- Earning Date
- ACAD 08-06-2025
- LEU 10-27-2025
- Dividend Yield
- ACAD N/A
- LEU N/A
- EPS Growth
- ACAD 615.00
- LEU 10.12
- EPS
- ACAD 1.33
- LEU 6.16
- Revenue
- ACAD $1,018,885,000.00
- LEU $436,900,000.00
- Revenue This Year
- ACAD $14.01
- LEU $3.52
- Revenue Next Year
- ACAD $11.72
- LEU $8.01
- P/E Ratio
- ACAD $19.61
- LEU $32.77
- Revenue Growth
- ACAD 14.41
- LEU 12.72
- 52 Week Low
- ACAD $13.40
- LEU $34.91
- 52 Week High
- ACAD $26.65
- LEU $264.90
- Technical
- Relative Strength Index (RSI)
- ACAD 62.55
- LEU 51.05
- Support Level
- ACAD $25.14
- LEU $162.10
- Resistance Level
- ACAD $26.65
- LEU $215.29
- Average True Range (ATR)
- ACAD 0.67
- LEU 13.28
- MACD
- ACAD 0.04
- LEU 1.11
- Stochastic Oscillator
- ACAD 70.27
- LEU 58.13
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
About LEU Centrus Energy Corp.
Centrus Energy Corp is engaged in the supply of nuclear fuel and services for the nuclear power industry. It operates through the Low-Enriched Uranium (LEU) and Technical Solutions segments. The LEU segment has two components which include the sale of separative work units and uranium. The Technical Solutions segment provides engineering, design, and manufacturing services to government and private sector customers. The majority of the firm's revenue is derived from the LEU segment. It has a business presence in the U.S. and other countries, of which prime revenue is generated in the U.S.